ArticleCureus2025
Evaluating Platelet-to-Lymphocyte Ratio and Systemic Immune-Inflammation Index as Distinctive Biomarkers in Type 2 Diabetes Mellitus Patients With and Without Proteinuria: A Retrospective Study.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Development and validation of an early risk prediction model based on inflammatory and metabolically derived markers for early diagnosis of diabetic kidney disease.Scientific reports · 2026Article
- Association of Inflammatory-Hematological Biomarkers with Hypertension and Related Comorbidities.Journal of clinical medicine · 2026Article
- Comprehensive Evaluation of Non-Standard Inflammatory and Metabolic Indices in Obesity: A Single-Center Retrospective Study.Healthcare (Basel, Switzerland) · 2025Article
- Associations between systemic inflammatory indices and the risk of renal function decline in patients with type 2 diabetes mellitus: a retrospective cohort study.Frontiers in endocrinology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Diabetic kidney disease (DKD), a leading cause of chronic kidney disease (CKD) and end-stage renal disease globally, is driven by metabolic and inflammatory processes. Systemic immune-inflammation index (SII) and platelet-to-lymphocyte ratio (PLR) are emerging biomarkers that integrate inflammatory and hematological components, potentially reflecting severity of renal dysfunction. Methods This retrospective study analyzed 160 patients from January 2023 to December 2023 with type 2 diabetes mellitus (T2DM), equally divided into proteinuria and non-proteinuria groups. SII and PLR levels were compared between groups, and their correlations with urine albumin-to-creatinine ratio (ACR) and protein levels were evaluated using statistical measures, including Pearson's correlation and regression analyses. Results SII and PLR levels were significantly higher in the proteinuria group (SII: 1,305,266 vs. 456,957.4 cells per microliter; PLR: 252.09 vs. 99.74, p<0.001 for both). SII and PLR exhibited strong positive correlations with urine ACR (SII: r=0.8537, PLR: r=0.8362) and protein levels (SII: r=0.834, PLR: r=0.841, p<0.01 for both). Regression analysis revealed a complex, nonlinear association between these biomarkers and increasing proteinuria severity, indicating their dynamic behavior across protein categories. HbA1c demonstrated a parabolic relationship with urine ACR, with progressively larger effects at higher levels, highlighting its role in worsening renal dysfunction. Conclusion SII and PLR are robust markers of inflammation and renal injury in T2DM, showing strong associations with proteinuria and urine ACR. These indices, alongside HbA1c, may aid in early detection and monitoring of DKD progression, particularly in resource-constrained settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.